TEVA News

Teva to Present at the Upcoming Investor Conferences in March

Medincell to Present at the TD Cowen 46 th Annual Healthcare Conference in Boston, March 2-4, 2026

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAI

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dactinomycin Market Research Report 2026-2030 & 2035: $7.83 Billion Market Driven by Expansion of Cancer Centers, Emphasis on Pediatric Oncology, and Combination Therapy Research

Interact Expands its Employee Experience Platform with New AI‑Native Features and Workday Integration

$ORCL Fraud Allegations: Oracle Corporation 11% Stock Drop Triggers Securities Fraud Class Action, Investors Notified to Contact BFA Law by April 6 to Protect Your Rights Ready to Announce with Confidence?

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease